Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Search
Brigimadlin (BI 907828)
Brigimadlin BI 907828
Meet the Partnering Team Video 2023
Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.
Anti-fibrotic agent
Anti-fibrotic agent
bix_facilitates_global_partnerships
BI X focuses on partnerships to speed up the development of digital healthcare solutions
Ridgefield
Ridgefield is home to the company’s US headquarters. The site serves as a key research center for human pharmaceuticals.
Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
C3-binding polypeptide
C3-binding polypeptide
Modified yersinia
Modified yersinia
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
VSV-GP
VSV-GP
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody
GLP-1/FGF21 agonist
GLP-1/FGF21 agonist
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
SIRPα antagonist
SIRPα antagonist
CD137/FAP agonist
CD137/FAP agonist
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
KRAS multi-inhibitor
KRAS multi-inhibitor
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
NPY2r agonist
Food intake regulator
Science Focus
Science Focus
Survodutide (BI 456906)
BI 456909
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Boehringer Ingelheim acquires a stake in SoundTalks
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme